SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- HIV
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DewDiligence_on_SI who wrote (85)2/21/2009 9:13:03 PM
From: Elroy Jetson  Read Replies (1) of 155
 
The concept of "improved compliance" with a single tablet has been much promoted by some pharma firms. Apparently you believe them.

Yet there is no evidence that patients are more likely to take one large tablet, than three smaller ones, once a day.

There is some evidence that compliance is higher with once a day regimens than twice a day regimens. But there's an equal amount of evidence that the downside of a missed dose is greater with a once a day combination than with a twice a day combination.

The improved market share for combination tablets has been bought at the expense of profitability.
.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News